Head to Head Contrast: Aileron Therapeutics (NASDAQ:ALRN) versus Tharimmune (NASDAQ:THAR)

Aileron Therapeutics (NASDAQ:ALRN) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Risk and Volatility

Aileron Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Profitability

This table compares Aileron Therapeutics and Tharimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aileron Therapeutics	N/A	-84.88%	-30.81%
Tharimmune	N/A	-144.13%	-113.57%

Insider and Institutional Ownership

90.9% of Aileron Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 5.6% of Aileron Therapeutics shares are held by insiders. Comparatively, 2.4% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Aileron Therapeutics and Tharimmune, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aileron Therapeutics	0	0	1	1	3.50
Tharimmune	0	0	0	0	N/A

Aileron Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 436.72%. Given Aileron Therapeutics’ higher possible upside, analysts plainly believe Aileron Therapeutics is more favorable than Tharimmune.

Valuation & Earnings

This table compares Aileron Therapeutics and Tharimmune”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aileron Therapeutics	N/A	N/A	-$15.73 million	($3.19)	-1.11
Tharimmune	N/A	N/A	-$9.32 million	N/A	N/A

Summary

Aileron Therapeutics beats Tharimmune on 8 of the 9 factors compared between the two stocks.

About Aileron Therapeutics

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.